General Administration of Sport of China

World Cyber Security Summit in Jordan brought together global cyber security experts to tackle the battle against cyber threats

Retrieved on: 
Thursday, September 22, 2022

The event's organiser, Trescon and its Strategic Partner JOCSA (Jordan Cyber Security Association) hosted more than 500 C-level attendees, including key stakeholders in the cyber security ecosystem, such as government officials, top experts in the field, solution providers, startups, media, among others.

Key Points: 
  • The event's organiser, Trescon and its Strategic Partner JOCSA (Jordan Cyber Security Association) hosted more than 500 C-level attendees, including key stakeholders in the cyber security ecosystem, such as government officials, top experts in the field, solution providers, startups, media, among others.
  • A picture of the panel discussion from the World Cyber Security Summit – Jordan that was streamed live on August 15-16, 2022
    Leading players in Cyber security space like Green Circle , Agualetica , BeeezCrowd , Alpha Hub , Mandiant , CloudSEK , ManageEngine, and Wizard Cyber gathered at the event to examine the prospects for Cyber Security in Jordan.
  • Abdulrahman Al-Nimari, VP, Cyber Security from Saudi Arabia spoke at length on ‘Zero Trusting Your Enterprise.
  • The 17th global edition of World Cyber Security Summit – Jordan is supported by Hashemite Kingdom of Jordan and the Ministry of Digital Economy and Entrepreneurship, Jordan and officially sponsored by:

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Monday, August 15, 2022

WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, today announced financial results and business highlights for the second quarter ended June 30, 2022.

Key Points: 
  • WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, today announced financial results and business highlights for the second quarter ended June 30, 2022.
  • Adagio intends to initiate clinical development of select antibodies in the first quarter of 2023.
  • Research & Development (R&D) Expenses: R&D expenses were $37.1 million for the second quarter of 2022, compared to $35.1 million for the comparable period of 2021.
  • Basic and diluted net loss per share was $0.47 for the second quarter of 2022, compared to $178.86 for the comparable period in 2021.

TFF Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 11, 2022

FORT WORTH, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the second quarter of 2022 and provided an update on recent corporate and clinical developments. The Company will discuss the highlights on a conference call and webcast, scheduled for today, Thursday, August 11, 2022, at 4:30 PM ET.

Key Points: 
  • We believe the second half of the year is shaping up to be a very exciting period for TFF Pharmaceuticals.
  • Research and Development (R&D) expenses: R&D expenses for the second quarter of 2022 were $5.1 million, compared to $2.8 million in 2021.
  • General & Administrative (G&A) expenses: G&A expenses for the second quarter of 2022 were $3.7 million, compared to $2.4 million in 2021.
  • Net Loss: TFF Pharmaceuticals reported a net loss for the second quarter of 2022 of $8.7 million, compared to a net loss of $4.7 million in 2021.

Optinose Reports Second Quarter 2022 Financial Results and Operational Updates

Retrieved on: 
Thursday, August 11, 2022

Conference call and webcast to be held today at 8:00 a.m. Eastern Time

Key Points: 
  • Conference call and webcast to be held today at 8:00 a.m. Eastern Time
    YARDLEY, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2022, and provided operational updates.
  • We reported confirmatory, positive topline results from ReOpen2 in June and are further encouraged by the consistency observed in key secondary and pooled results," stated CEO Peter Miller.
  • Our current business is performing well, XHANCE net revenue increased 12% in the second quarter of 2022 compared to second quarter 2021 and increased 21% on a year-to-date basis.
  • Members of the Companys leadership team will host a conference call and presentation to discuss financial results and corporate updates beginning at 8:00 a.m. Eastern Time today.

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022

BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the second quarter ended June 30, 2022 and highlighted recent business updates.

Key Points: 
  • We continued to make significant progress in advancing our growing pipeline of EEV therapeutic candidates during the second quarter, said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • Research & Development (R&D) Expenses: R&D expenses for the second quarter of 2022 were $16.2 million, compared to $6.8 million for the same period in 2021.
  • General & Administrative (G&A) Expenses: G&A expenses for the second quarter of 2022 were $7.3 million, compared to $3.1 million for the same period in 2021.
  • Net Loss: Net loss for the second quarter of 2022 was $23.2 million, compared to $9.9 million for the same period of 2021.

Battle against cyber threats to be addressed by cyber security visionaries at #WCSSJordan

Retrieved on: 
Thursday, August 11, 2022

The 17th global edition of World Cyber Security Summit is gearing up with the goal of constructing a security framework for organisations in Jordan.

Key Points: 
  • The 17th global edition of World Cyber Security Summit is gearing up with the goal of constructing a security framework for organisations in Jordan.
  • Amman, Jordan, Aug 11, 2022 - (ACN Newswire) - The 17th global edition of World Cyber Security Summit will be held under the auspices of H.E.
  • In order for effective implementation of these policies, World Cyber Security Summit will play its part by providing a platform to conduct thorough debates, and deliberations on the proposed cyber security strategies.
  • "We're happy to bring the global series of World Cyber Security Summit to Jordan, with the support of our Strategic Partner, Jordan Cyber Security Awareness Association (JOCSA).

Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 9, 2022

XTX202, a tumor-selective, engineered IL-2, is being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors.

Key Points: 
  • XTX202, a tumor-selective, engineered IL-2, is being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors.
  • Xilio anticipates the data for Part 1A will include available safety and anti-tumor activity, as well as peripheral PK and PD data.
  • Xilio anticipates the data for Part 1B will include available safety and anti-tumor activity, as well as intra-tumoral PK and PD data.
  • Net Loss: Net loss was $24.6 million for the second quarter of 2022, compared to $23.2 million for the second quarter of 2021.

Rallybio Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent program and corporate developments.

Key Points: 
  • Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent program and corporate developments.
  • Rallybio expects to discuss the preliminary platelet elimination data by the end of the third quarter of 2022 and to release PoC data in the first quarter of 2023.
  • Rallybio announced in June 2022 that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer (CFO).
  • Second Quarter 2022 Financial Results:
    Research & Development (R&D) Expenses: R&D expenses were $10.1 million for the second quarter of 2022, compared to $6.8 million for the same period in 2021.

Help Fulfil the Dream of Building a Leading Sports Nation and Empower Healthy China

Retrieved on: 
Monday, August 8, 2022

BEIJING, Aug. 8, 2022 /PRNewswire/ -- The Press Briefing of China Sports Culture Expo and China Sports Tourism Expo 2022 (hereinafter referred to as "CSCTE 2022") and Investment Promotion Conference was held in Guangzhou on August 3. It was officially announced that CSCTE 2022 is scheduled to be held on November 25-27 at Poly World Trade Center Expo in Guangzhou.

Key Points: 
  • The Outline for Building a Leading Sports Nation is being implemented across the board, and the efforts to build a leading sports nation are underway.
  • The dream of making China a country strong on sports is being integrated into the Chinese Dream.
  • CSCTE 2022 will accelerate the integrated development of sports and culture & tourism, and give an impetus to the realization of the dream of building a leading sports nation and the dream of China's rejuvenation.
  • China Sports Tourism Expo, hosted by All-China Sports Federation, Chinese Olympic Committee and China Tourism Association, is a high-level expo in the sports tourism industry.

Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Monday, August 8, 2022

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended June 30, 2022, and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended June 30, 2022, and highlighted recent progress.
  • The Company plans to complete enrollment of all four cohorts of the trial in the second half of this year.
  • The Company expects to report topline results from Part A, initiate Part B and discuss the data with regulatory authorities during the second half of 2022.
  • Verastem Oncology ended the second quarter 2022 with cash, cash equivalents and investments of $94.3 million.